| http://www.w3.org/ns/prov#value | - What: Shares of bluebird bio (NASDAQ: BLUE ) , a clinical-stage biopharmaceutical company developing gene-based therapies to treat orphan diseases and other genetic disorders, stumbled as much as 10% after announcing its intention to offer common stock after the closing bell last night.
|
